Parkinson Disease

Experts explore how stem cell therapies could transform the treatment of Parkinson disease, covering clinical trial progress, patient counseling challenges, and the potential to replace current standard-of-care approaches.

Early data from the Clinical Nurse Navigator program show that more than 99% of patients with Parkinson's disease reaching a first optimization dose of continuous subcutaneous apomorphine infusion did so without antiemetic pretreatment.

The CEO and founder of Yes, And...eXercise (YAX) discussed how support groups, psychosocial connection, and hybrid telehealth models can complement pharmacologic treatment in Parkinson disease. [WATCH TIME: 3 minutes]

Exploratory post hoc data suggest prompt pimavanserin initiation within 6 to 12 months of PDP onset may yield a more favorable symptom trajectory, though prospective confirmation is needed.

In this final episode, Roger Barker, MD, PhD, and Claire Henchcliffe, MD, DPhil, discuss why neurologists should stay informed on stem cell medicine and the broader implications of regenerative therapies across neurology.

Neurologists Roger Barker, MD, PhD, and Claire Henchcliffe, MD, DPhil, discuss how stem cell therapies may differ from existing Parkinson disease treatments and the potential benefits of dopamine cell replacement.

Roger Barker, MD, PhD, and Claire Henchcliffe, MD, DPhil, examine the expanding clinical trial landscape for stem cell therapies in Parkinson disease and the programs leading development efforts.

From patient questions to clinical trial referrals, this episode highlights practical strategies for counseling individuals interested in stem cell-based therapies for Parkinson disease.

Kelsey Jensen, MD, a movement disorders neurologist at Allina Health, discussed Parkinson disease diagnosis, deep brain stimulation candidacy, treatment personalization, and ongoing unmet needs in PD care and research.

Experts shared their clinical perspectives and insights on main focus areas at the 2026 American Academy of Neurology (AAN) Annual Meeting, held April 18-22 in Chicago, Illinois.

Kinan Muhammed, MD, PhD, consultant neurologist and co-founder and Chief Medical Officer for Kneu Health, discussed how smartphone-based remote monitoring tools may help clinicians track motor and cognitive changes in Parkinson disease and dementia more continuously.

The director of the Center for Neurological Restoration at Cleveland Clinic discussed long-term TEMPO-4 data evaluating tavapadon’s impact on symptom control and levodopa utilization in Parkinson disease.

A duo of Baptist Health experts discussed emerging evidence suggesting that hormonal factors, sex-based clinical differences, and social roles contribute to distinct experiences for women with Parkinson disease.

A recent study suggested that probiotic regimens and biomarker-guided strategies may be a promising signal for reducing excessive daytime sleepiness in patients with PD and CKD.

New findings from a post hoc analysis of 2 phase 3 trials, presented at AAN 2026, reported that a majority of participants with advanced Parkinson disease had no troublesome dyskinesia at follow-up.

The president at Cala Health discussed the clinical role, evidence base, and potential of the Cala kIQ Plus wearable TAPS therapy for patients with essential tremor and Parkinson disease at AAN 2026.

Real-world data of the ELEVATE-PD study, presented at AAN 2026, suggest that switching to IPX203 from other levodopa-based therapies may improve motor function in patients with Parkinson disease.

In recognition of National Public Health Week, held April 6-12, NeurologyLive summarizes recent literature showing that environmental exposures are associated with increased risk of neurologic disorders.

In a preclinical study, subthalamic nucleus (STN) low-beta power negatively correlated with wake quantity, whereas STN and motor cortex high-beta power demonstrated a positive correlation with wakefulness.

A new retrospective analysis presented at AD/PD 2026 showed that cutaneous phosphorylated α-synuclein testing reduced diagnostic and management-related health care expenditures.

An analysis of baseline data from the phase 2b LUMA study suggested that keystroke dynamics captured through a smartphone-based typing task could provide a reliable method for assessing disease progression in Parkinson disease.

Early ASPIRO trial data show autologous stem-cell dopamine precursors stay safe at 12 months, with improved PD motor scores and PET-confirmed grafting.

UK platform trial enrolls 1,600 with Parkinson’s to rapidly test telmisartan, terazosin and new candidates via shared placebo and virtual visits.

Xenos Mason, MD, a neurologist specializing in movement disorders, provides commentary on an early-stage study evaluating induced pluripotent stem cells for patients with Parkinson disease.

A phase 2a trial showed that NLX-112 was safe and well tolerated in patients with Parkinson disease, while also reducing levodopa-induced dyskinesia and motor symptoms, supporting further clinical development.